[Comunicado de imprensa – Ainda não publicado] Vacina da Novavax contra COVID-19 demonstra 90% de eficácia geral e 100% de proteção contra doença moderada e grave.
15 Jun, 2021 | 11:35hComunicado de imprensa: Novavax COVID-19 Vaccine Demonstrates 90% Overall Efficacy and 100% Protection Against Moderate and Severe Disease in PREVENT-19 Phase 3 Trial
Comentários: U.S. clinical trial results show Novavax vaccine is safe and prevents COVID-19 – NIH News Releases E Novavax Covid-19 vaccine highly effective in late-stage trial, long-awaited results show – STAT E Powerful new COVID-19 vaccine shows 90% efficacy, could boost world’s supply – Science E Novavax COVID vaccine 90% effective in phase 3 trial – CIDRAP E What the Novavax vaccine means for the global fight against Covid-19 – Vox
Comentário no Twitter (fio – clique para saber mais)
Good news—Novavax protein-subunit vaccine phase 3 trial shown to to be 90.4% effective overall, 100% against moderate to severe disease. This is different type from mRNA and from AZ/J&J adenovirus vaccines, and different from inactivated types. #COVID19 https://t.co/ajoGhaOUu9
— Eric Feigl-Ding (@DrEricDing) June 14, 2021